Vasopressin-stimulated Phosphoinositide Hydrolysis in Cultured Rat Inner Medullary Collecting Duct Cells Is Mediated by the Oxytocin Receptor

Isaac Teitelbaum
With the technical assistance of Alexia Strasheim
Department of Medicine, University of Colorado School of Medicine, Denver, Colorado 80262

Abstract

Studies were performed to identify the receptor that mediates AVP-stimulated phosphoinositide (PI) hydrolysis in cultured rat inner medullary collecting tubule (RIMCT) cells. While the selective V1 receptor agonist [Ho1, Phe2, Ora3] VT has no effect on inositol trisphosphate (IP3) production over the range of 10^{-12} to 10^{-7} M, the selective V2 receptor agonist VDAVP stimulates IP3 production in dose-dependent fashion. Oxytocin stimulates IP3 production in dose-dependent fashion as well. AVP-stimulated phospholipase C activity is not inhibited by the V1 receptor antagonist d(CH2)2Tyr(Me)AVP (10^{-7} M) but is eliminated by the V2 receptor antagonist d(CH2)2Tyr(Me)-Thr4OVT (10^{-7} M) does not inhibit AVP-stimulated cAMP production. The selective oxytocin receptor antagonist [Thr4, Gly3] oxytocin does not stimulate cAMP production in RIMCT cells but does promote PI hydrolysis. The selective oxytocin receptor antagonist desGlyNH2-d(CH2)2Tyr(Me)-Thr4OVT (10^{-7} M) does not inhibit AVP-stimulated cAMP production but eliminates IP3 production in response to AVP or the V2 receptor agonist VDAVP. These studies demonstrate that AVP or V2 receptor agonist stimulate PI hydrolysis in cultured RIMCT cells via occupancy of the oxytocin receptor.

Methods

Cell culture. Cultures of RIMCT cells were prepared as previously described (7, 8) to yield a homogeneous population of nonintertcalated cells (9). For studies on cAMP production, tissue from two rats was used to plate one 24-well Costar dish; for studies on inositol trisphosphate (IP3) production wells were plated at three times this density to obtain uniform confluent cultures.

Determination of inositol phosphates. At 96 h the Hams F12/Liebovitz L15 medium in which the cells were initially grown was aspirated and the cultures washed twice with sterile PBS. The cells were then fed with inositol-free DMEM supplemented with 2H-hydroxy-2-inositol (5 μCi/well; Amersham Corp., Arlington Heights, IL). Studies were performed after 24 h of labeling, as this time has been demonstrated to be sufficient for incorporation into the phospholipid pool. Media was aspirated from the cells and the cells were washed twice with 500 μL of PBS. The buffer was then aspirated and replaced with 500 μL of PBS without or with the desired agonists and antagonists. The V1, V2, and oxytocin receptor agonists and antagonists employed in this study were all a generous gift from Dr. Maurice Manning (Medical College of Ohio, Toledo). Although not determined in RIMCT cells, the relative potencies of these compounds at the diuretic (V2), vasopressor (V1), and oxytocin receptors in rat tissues is shown in Table I. These values served as guidelines in the selection of test compounds.

Preliminary studies demonstrated that AVP-stimulated IP3 production in RIMCT cells peaks at 10 s. Therefore, all studies were performed for 10 s at which time the reaction was terminated by the addition of 500 μL of ice-cold 20% TCA. The cells were scraped off of the dish and centrifuged at 1,000 g for 10 min. The supernate containing inositol phosphates was washed four times with an equal volume of ether and stored at -20°C until analysis. Inositol phosphates were separated by anion exchange chromatography as described by Berridge et al. (15) and previously reported from this laboratory (8, 16). Results are expressed as cpm of IP3 per well.

Determination of cAMP production. Studies were performed in Krebs-Ringer’s buffer, pH 7.4, at 300 mOsm/kg H2O in the presence of 0.5 mM isobutylmethylxanthine to inhibit phosphodiesterase. Incubation with effector solutions and subsequent determinations of cAMP and protein were performed as reported previously (7, 9). Results are expressed as fmol cAMP/μg protein.

Previous studies have demonstrated a reciprocal relationship between AVP-stimulated adenyl cyclase (AC) and PLC activities in RIMCT cells (17). AVP stimulates AC in dose-dependent fashion; the ensuing increase in cellular cAMP content inhibits PLC (17, 18). Con-
sequently, AVP-stimulated IP3 generation is greatest at concentrations of the peptide at which no cAMP accumulation is observed. In this study, therefore, AVP is employed at 10^{-11} M when examining its effect on PLC and at 10^{-7} M when examining its effect on AC.

Statistical analysis. In studies on cAMP production, values obtained in triplicate wells are means of an "n" of one; in studies on IP3 production each well is considered an "n" of one. Comparisons between two treatment groups are by the unpaired t test (19). In all circumstances P < 0.05 is considered significant. Data are presented as mean±SEM.

Results

Effect of V1 and V2 receptor agonists. The initial set of experiments examined the response to selective AVP V1 or V2 receptor agonists. As seen in Fig. 1, the V1 receptor agonist [Ho^1, Phe^2, Orn^4]VT (Table I) does not stimulate IP3 production over the range of 10^{-11}–10^{-7} M. In contrast, a response to the V2 receptor agonist VDAVP (Table I) is observed at a concentration as low as 10^{-11} M (2350±370 cpm/well vs. 940±275, basal; n = 5, P < 0.02) increasing further at 10^{-9} M with a plateau at 10^{-7} M.

Effect of V1 and V2 receptor antagonists. The effect of V1 and V2 receptor antagonists is shown in Fig. 2. AVP (10^{-11} M) stimulates IP3 production from 699±230 to 5748±670 cpm/well (n = 4, P < 0.001). Coincubation with the V1 receptor antagonist d(CH_2)_3Tyr(Me)AVP (10^{-7} M) (Table I) has no effect on the response to AVP (5399±752). In contrast, coincubation with the V2 receptor antagonist d(CH_2)_3D Tyr(Et)VAVP (10^{-7} M) (Table I) abolishes stimulation by AVP (526±184; NS vs. basal). Thus, AVP-stimulated PLC activity in cultured RIMCT cells is not mediated by the V1 receptor; it is mimicked by a V2 receptor agonist and is inhibited by a V2 receptor antagonist.

Effect of oxytocin. Since oxytocin had been shown to stimulate PLC in LLC-PK1 cells (1), we next examined the ability of oxytocin to stimulate PLC in RIMCT cells. As seen in Fig. 3, a significant response to oxytocin is observed at a concentration as low as 10^{-11} M (2285±392 cpm/well vs. 940±275, basal; n = 5, P < 0.05) and the response increases in dose-dependent fashion thereafter. To determine whether the stimulation observed in response to the V2 receptor agonist VDAVP or oxytocin might be mediated by a common receptor, we examined the ability of the V2 receptor antagonist to inhibit the response to oxytocin. As seen in Fig. 4, coincubation with the V2 antagonist d(CH_2)_3D Tyr(Et)VAVP (10^{-7} M) eliminates the response to oxytocin (4551±376 vs. 638±213 cpm/well; n = 4, P < 0.001). In fact, as seen in Table I, this compound actually has greater antioxytocic potency than it does antidiuretic potency. Likewise, oxytocin itself (10^{-8} M) cross-reacts with the V2 receptor as it stimulates cAMP accumulation from 29.57±2.41 to 63.64±7.33 fmol/µg protein (n = 5, P < 0.01). The question then arises, which receptor mediates AVP-stimulated PLC activity in RIMCT cells, V2, or oxytocin?

Effect of a selective oxytocin receptor agonist and antagonist. To address this question, we employed a highly selective oxytocin agonist and antagonist (Table I), which unlike oxytocin, exhibit no appreciable cross-reactivity with the V2 receptor. As seen in Fig. 5, the selective oxytocin agonist (Thr^4, Gly^5) oxytocin (10^{-7} M) (Table I) does not stimulate cAMP production in RIMCT cells (22.10±5.04 vs. 20.97±5.67 fmol/µg protein; n = 3, NS). Similarly, the selective oxytocin receptor antagonist desGly_NH_d(CH_2)_3[Tyr(Me)Thr^4]OVT (10^{-7} M) (Table I) does not inhibit AVP-stimulated cAMP accumulation (337.38±34.64 vs. 349.92±57.16 fmol/µg protein; n = 3, NS). Therefore, these compounds are in fact selective for the oxytocin receptor, and at the concentrations employed exhibit no activity at the V2 receptor.

Fig. 6 depicts the dose-response curve to the selective oxytocin agonist (Thr^4, Gly^5) oxytocin. A response is observed at a concentration as low as 10^{-11} M (2143±553 vs. 352±116 cpm/
well; \( n = 4, P < 0.02 \) and increases dose-dependently thereafter. Coincubation with the selective oxytocin receptor antagonist (10\(^{-7}\) M) inhibits the response to (Thr\(^{4}\), Gly\(^{7}\)) oxytocin (3838±715 vs. 250±122 at 10\(^{-11}\) M, \( P < 0.005 \) and 6340±597 vs. 3702±809 at 10\(^{-7}\) M, \( P < 0.05 \)). In contrast, the V\(_{1}\) receptor antagonist (10\(^{-7}\) M) does not inhibit the response to 10\(^{-7}\) M (Thr\(^{4}\), Gly\(^{7}\)) oxytocin (5588±76 vs. 5280±215; \( n = 3, NS \)). As seen in Fig. 7, coincubation with the selective oxytocin receptor antagonist also eliminates the response to 10\(^{-13}\) M AVP (4527±122 vs. 1167±134 cpm/well; \( n = 4, P < 0.001 \)). Similarly, as seen in Fig. 8, stimulation of PLC by the V\(_{2}\) agonist VDAVP is eliminated in the presence of the oxytocin receptor antagonist. Furthermore, production of IP\(_{3}\) upon stimulation with 10\(^{-13}\) M AVP + 10\(^{-7}\) M (Thr\(^{4}\), Gly\(^{7}\)) oxytocin (7024±300 cpm/well) is no greater than in response to AVP alone (6732±270; \( n = 3, NS \)), indicating that the two agents act through a common receptor (Fig. 9). These data indicate that in RIMCT cells stimulation of PLC by AVP is mediated by the oxytocin receptor.

**Discussion**

AVP-stimulated phosphoinositide (PI) hydrolysis in hepatocytes and vascular smooth muscle cells is mediated by the AVP V\(_{1}\) receptor. Indeed, it is this property that defines the V\(_{1}\) receptor (20). A priori, therefore, one would predict PI hydrolysis in response to AVP to be mediated by the V\(_{1}\) receptor in other tissues, e.g., renal epithelia, as well. This has, in fact, been suggested to be the case in the LLC-PK\(_{1}\) cell, a porcine renal cell line of distal tubular origin (2, 3) and in the rabbit cortical collecting duct (4). In RIMCT cells, however, a selective V\(_{1}\) receptor agonist fails to stimulate PI hydrolysis (Fig. 1) and a selective V\(_{1}\) receptor antagonist fails to eliminate the response to AVP (Fig. 2). Rather, AVP-stimulated PI hydrolysis is reproduced by a V\(_{2}\) receptor agonist (Fig. 1) and is inhibited by a V\(_{2}\) receptor antagonist (Fig. 2), suggesting that both adenylyl cyclase and PLC are coupled to the V\(_{2}\) receptor. Although there is precedent for the notion of "receptor promiscuity," i.e., a single receptor coupling to more than one signaling system (21), the possibility that both AVP-stimulated adenylyl cyclase and PLC activities are mediated by the same receptor seems unlikely, especially as in RIMCT cells, each of these systems negatively modulates activity of the other (17, 18). Because AVP-stimulated PI hydrolysis in LLC-PK\(_{1}\) cells has been suggested to occur via occupancy of the oxytocin receptor (1), we considered the possibility that this might be the case in RIMCT cells as well and that the effects of the V\(_{2}\) receptor agonist and antagonist might be a consequence of cross-reactivity with the oxytocin receptor. We found that oxytocin does indeed stimulate PI hydrolysis in RIMCT cells in dose-dependent fashion (Fig. 3) and that this response is eliminated by the V\(_{2}\) receptor antagonist d(CH\(_{2}\))\(_{4}\)Tyr(Et)VAVP (Fig. 4), which is known to exhibit cross-reactivity with the oxytocin receptor (Table I).

Oxytocin has been reported to produce hyponatremia in humans (22, 23), indicating that it has activity at the V\(_{2}\) receptor. Autoradiographic studies have demonstrated specific oxytocin binding sites in the papillary region of the rat kidney (24) and we have found significant stimulation of cAMP production by oxytocin in RIMCT cells (see Results). Therefore, to define whether AVP-stimulated PI hydrolysis is mediated by the V\(_{2}\) or the oxytocin receptor, it was necessary that we employed a highly oxytocin-selective agonist and antagonist neither of which exhibits activity at the V\(_{2}\) receptor (Fig. 5). The observations that a highly selective oxytocin agonist with no stimulatory activity at the V\(_{2}\) receptor stimulates PLC (Fig. 6) and that a highly selective oxytocin antagonist that does not inhibit AVP-stimulated cAMP accumulation eliminates stimulation of PLC in response to either AVP (Fig. 7) or the V\(_{2}\) agonist VDAVP (Fig. 8), clearly indicate that AVP-stimulated PI hydrolysis in RIMCT cells is mediated by the oxytocin receptor. Further support for the response to AVP being mediated by the oxytocin receptor derived from the observation that maximal AVP-stimulated IP\(_{3}\) production is not augmented by the addition of 10\(^{-7}\) M (Thr\(^{4}\), Gly\(^{7}\)) oxytocin (Fig. 9).

Our findings are in accord with those obtained by Stassen et al. in LLC-PK\(_{1}\) cells where oxytocin was demonstrated to stimulate PLC (1). Likewise, our findings are compatible with those previously obtained in rat inner medullary collecting ducts in which AVP-stimulated PLC activity was reported to occur in response to a V\(_{2}\) receptor agonist (5, 6); in these studies, the possibility that the effect of the V\(_{2}\) agonist might be mediated...
by the oxytocin receptor was not examined. In contrast, our findings differ from those of Burnatowska-Hledin and Spielman who found that the ability of AVP to cause a Ca\(^{2+}\) transient in both LLC-PK\(_1\) cells (2) and rabbit cortical collecting duct principal cells (4) was inhibited by the same V\(_1\) receptor antagonist used in this study. Similarly, in their study in LLC-PK\(_1\) cells (3), Weinberg et al. were able to inhibit the response to AVP with two different V\(_1\) antagonists and concluded that AVP-stimulated PI hydrolysis in this cell line is mediated by the V\(_1\) receptor. While this may reflect heterogeneity of the nephron segment under study or species variation, it should be noted that in those studies the V\(_1\) antagonists were used at concentrations 10–100 times that of employed in this study, i.e., 10\(^{-5}\)–10\(^{-3}\) M. Each of the V\(_1\) antagonists employed has substantial antioxytocic potency as well, ranging from 1 to 35% of their antivasopressor potencies (13, 25). Indeed, we have found that while the V\(_1\) antagonist d(CH\(_2\))\(_{2}\)Tyr(Me)AVP used at 10\(^{-7}\) M does not inhibit PI hydrolysis in response to the selective oxytocin agonist (Thr\(^4\), Gly\(^2\)) oxytocin (5588±76 cpm/well, oxytocin agonist vs. 5380±215, agonist + V\(_1\) antagonist; n = 3, NS), when used at concentrations of 10\(^{-6}\) M (3372±90; n = 3, P < 0.001 vs. oxytocin agonist alone) or 10\(^{-5}\) M (2156±307) it does. Similarly, while the V\(_1\) antagonist used at 10\(^{-7}\) M failed to inhibit AVP-stimulated PI hydrolysis (See Fig. 2) when employed at 10\(^{-5}\) M it does (6732±270 vs. 3216±282 cpm/well; n = 3, P < 0.001). Thus, the data of Burnatowska-Hledin and Spielman (2, 4) and of Weinberg et al. (3) may also reflect AVP-stimulated PI hydrolysis being mediated by the oxytocin receptor. On the basis of our findings that (a) at sufficiently high concentrations either the V\(_2\) or the V\(_3\) receptor antagonist cross-reacts with the oxytocin receptor; (b) the response to AVP is eliminated by large concentrations of either the V\(_2\) or the V\(_3\) antagonist; (c) a selective V\(_2\) agonist does not stimulate PI hydrolysis in dose-dependent fashion, whereas (d) a highly selective oxytocin agonist does; and (e) AVP-stimulated PI hydrolysis is eliminated by a highly selective oxytocin antagonist, we conclude that it is, in fact, the oxytocin receptor that mediates AVP-stimulated phosphoinositol hydrolysis in RIMC-T cells and probably throughout the distal mammalian nephron. It should be noted, however, that as these studies were performed in cultured cells, further studies will be required to determine whether oxytocin promotes an increase in cytosolic calcium in the inner medullary collecting duct in vivo.

**Figure 7.** Effect of the selective oxytocin receptor antagonist desGly\(_4\)NH\(_2\)d(CH\(_2\))\(_3\)Tyr(Me)Thr\(^{9}\)VOT (10\(^{-7}\) M) on AVP-stimulated IP\(_3\) production (n = 4).

**Figure 8.** Effect of desGly\(_4\)NH\(_2\)d(CH\(_2\))\(_3\)Tyr(Me)Thr\(^{9}\)VOT (10\(^{-7}\) M) on VDAVP-stimulated IP\(_3\) production (n = 3).

**Figure 9.** Effect of the selective oxytocin agonist (Thr\(^4\), Gly\(^2\)) oxytocin on AVP-stimulated IP\(_3\) production (n = 3). Addition of the oxytocin agonist does not augment the response to AVP.

Maneuvers that stimulate AVP release from the posterior pituitary (e.g., hemorrhage, increased plasma osmolality, or the intraventricular administration of carbachol or angiotensin II) result in increased plasma oxytocin levels as well (26–28). Whether, in normal physiology, the oxytocin receptor in the mammalian kidney is occupied by oxytocin or by the related neuroepitope, AVP is uncertain. It is clear that occupancy of the receptor results in stimulation of PLC and hydrolysis of PI. The role of AVP- or oxytocin-stimulated PI hydrolysis in modulating the hydroosmotic response to AVP is uncertain. One of the consequences of PI hydrolysis is activation of protein kinase C which inhibits the hydroosmotic response to AVP both pre- and post-cAMP (18, 29, 30). This suggests that stimulation of PLC by AVP might be involved in turning off the hydroosmotic response. Alternatively, generation of IP\(_3\) with a subsequent increase in cytosolic Ca\(^{2+}\) might be necessary for the development of the hydroosmotic responses. Preliminary data reported by Leite et al. support this possibility, as they observed no hydroosmotic response to AVP when cytosolic Ca\(^{2+}\) was chelated with TMB-8 (31). Lastly, one must consider the possibility that oxytocin receptor-stimulated PI hydrolysis mediates the natriuretic response to oxytocin (32, 33) but plays no role in modulation of the hydroosmotic response to AVP. Further studies will be required to define the physiologic role of AVP-stimulated PI hydrolysis that is mediated via the oxytocin receptor.

**Acknowledgments**

The authors wish to thank Ms. Linda M. Benson for secretarial assistance.

This work was supported by a grant from the National Institutes of Health (DK-38464).

**References**


7. Teitelbaum, I., and T. Berl. 1986. Effects of calcium on vasopressin-me-
diated cyclic adenosine monophosphate formation in cultured rat inner medul-
8. Teitelbaum, I., A. Strasheim, and T. Berl. 1990. Epidermal growth factor-
stimulated phosphoinositide hydrolysis in rat inner medullary collecting tubule 
85:1044-1050.
phosphocreatine generation in rat inner medullary collecting tubule cells. Kidney Int. 
35:647-653.
Structural changes in the arginine vasopressin molecule that enhance antidiuretic 
11. Lowbridge, J., and M. Manning. 1977. Synthesis and some pharmacologi-
cal properties of [4-Threonine, 7-glycine]oxytocin, [1-(L-2-Hydroxy-3-mercaptopro-
panoic acid),4-threonine,7-glycine]oxytocin (Hydroxy[Thr, Gly]oxytocin), and [7-Glycine]
oxytocin, peptides with high oxytocic-antidiuretic selectivity. J. Med. Chem. 20:120-123.
Design of more potent antagonists of the antidiuretic responses to arginine 
and antagonists of vasopressin and oxytocin. In Vasopressin, R. W. Schrier, edi-
synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
Irvine. 1983. Changes in the levels of inositol phosphates after agonist-dependent 
16. Teitelbaum, I. 1990. The epidermal growth factor receptor is coupled to a
phospholipase A2-specific pertussis-toxin-inhibitable guanine nucleotide-binding 
regulatory protein in cultured rat inner medullary collecting tubule cells. J. Biol. 
Chem. 265:4218-4222.
17. Teitelbaum, I., and A. Strasheim. 1990. AVP stimulates adenylyl cyclase 
and phospholipase C in reciprocal fashion in cultured RIMCt cells. Am. J. Phys-
iol. 259:C693-C696.
Invest. 86:46-51.
of phosphatidylinositol breakdown, with particular reference to the hepatic ef-
Caron. 1985. Specificity of the functional interactions of the β-adrenergic recep-
tor and rhodopsin with guanine nucleotide regulatory proteins reconstituted in 
graphic localization of vasopressin and oxytocin binding sites in rat kidney. 
Kidney Int. 33:959-965.
1985. Synthesis and some pharmacological properties of 18 potent O-alkylthio-
rine-substituted antagonists of the vasopressor responses to arginine vasopressin.
following osmotic activation of oxytocin neurones in the paraventricular and 
supraoptic nuclei. J. Physiol. 278:69-78.
hemorrhage and hypertonic saline upon plasma oxytocin and arginine vasopres-
29. Schlondorff, D., and S. D. Levine. 1985. Inhibition of vasopressin-stimu-
lated water flow in toad bladder by phorbol myristate acetate, dioctanoylglycerol,
acetate, dioctanoylglycerol, and phosphatidic acid inhibit the hydroosmotic effect
31. Leite, M., Jr., and W. N. Suki. 1989. TMB-8 inhibits the initiation phase but
not the sustained phase of AVP and dDAVP-activated hydroosmotic effect in 
1986. The influence of neurohypophysial hormones on renal function in the 
Physiol. 251:F290-F296.